Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis: Topics in Neuroscience
Autor O. R. Hommes, G. Comien Limba Engleză Hardback – 6 feb 2004
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 697.15 lei 6-8 săpt. | |
Springer – 28 sep 2012 | 697.15 lei 6-8 săpt. | |
Hardback (1) | 706.26 lei 6-8 săpt. | |
Springer – 6 feb 2004 | 706.26 lei 6-8 săpt. |
Preț: 706.26 lei
Preț vechi: 743.43 lei
-5% Nou
Puncte Express: 1059
Preț estimativ în valută:
135.18€ • 140.51$ • 111.97£
135.18€ • 140.51$ • 111.97£
Carte tipărită la comandă
Livrare economică 05-19 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9788847001954
ISBN-10: 8847001951
Pagini: 220
Ilustrații: XV, 199 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.54 kg
Ediția:2004
Editura: Springer
Colecția Springer
Seria Topics in Neuroscience
Locul publicării:Milano, Italy
ISBN-10: 8847001951
Pagini: 220
Ilustrații: XV, 199 p.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.54 kg
Ediția:2004
Editura: Springer
Colecția Springer
Seria Topics in Neuroscience
Locul publicării:Milano, Italy
Public țintă
ResearchCuprins
1 – Evidence for an Early Treatment of Multiple Sclerosis.- 2 – Inflammation, Demyelination, and Axonal Degeneraton: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1 H Treatment.- 3 – Genetic Regulation of Nerve Cell Death/Glial Activation and Protective Effects of Myelin Basic Protein Autoimmune Neurotrophin Production in Mechanically Induced Neurodegeneration.- 4 – Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: A Phase I/II Study with Riluzole.- 5 – Neuropathology and Disease Progression in Multiple Sclerosis.- 6 – Autoimmune Inflammation and Multiple Sclerosis.- 7 – Early Treatment of Progression in Multiple Sclerosis.- 8 – Imaging for Tissue Characterization in Multiple Sclerosis and Other White Matter Diseases.- 9 – Monounsaturated Fatty Acids and Neuroprotection. The Results of a Study of Cognitive Decline in Old Age. Is There a Case for this Treatment in Multiple Sclerosis?.- 10 – Neuroprotection in Acute Ischemic Stroke: Lessons for Early Treatment in Multiple Sclerosis.- 11 – Soluble VCAM-1 Release Indicates Inflammatory Blood-Brain Barrier Pathology and Further Modulates Adhesion.- 12 – Early Treatment in Multiple Sclerosis with Intravenous Immunoglobulin: Rationale and Study Design.- 13 – Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol.- 14 – T1-Hypointense Lesions (T1 Black Holes) in Mild-to-Moderate Disability Relapsing Multiple Sclerosis.- 15 – Acute Monosymptomatic Optic Neuritis: Potential Clues to Early Therapy in Multiple Sclerosis.- 16 – Antibody Mediated Demyelination.- 17 – Anti-MOG Antibodies as Early Predictors for Conversion to Relapsing-Remitting Disease Course inPatients Suggestive of Multiple Sclerosis.- 18 – Sunlight, Vitamin D, and Multiple Sclerosis.- 19 – The Yin and Yang of Inflammation in Multiple Sclerosis.- 20 – Management of Interferon-ß1b (Betaseron) Failures in Multiple Sclerosis with Interferon-?n3 (Alferon N).
Caracteristici
Updates the reader on evolution in the MS field New hypotheses and therapeutic options are presented